Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?

Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression re...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Warren Fingrut, Wendy Davis, Eric McGinnis, Karen Dallas, Khaled Ramadan, Hayley Merkeley, Heather Leitch, Yasser Abou Mourad, Ryan D. Cassaday, Camilla Ross, Chantal Léger
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2020-12-01
Schriftenreihe:	Current Oncology
Schlagworte:	inotuzumab ozogamicin cd22 acute lymphoblastic leukemia flow cytometry immunotherapy
Online-Zugang:	https://www.mdpi.com/1718-7729/28/1/27
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!